Change in Director(s)

To To Date: September 25, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Change in Designation of Directors and Reconstitution of Statutory Committees Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Members of the Company, at the 39th Annual General Meeting of the Company held on Thursday, September 24, 2026, have approved the following: a. Re-appointment of Mr. Ravindra Kumar Kothari (DIN: 03418320) as a Director liable to retire by rotation pursuant to Section 152 of the Companies Act, 2013. b. Change in designation of Mr. Ravindra Kumar Kothari (DIN: 03418320) from Non-Executive Director to Whole-Time Director, designated as Executive Director, with effect from October 1, 2026 c. Change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole-Time Director to Non-Executive Director, with effect from October 1, 2026. The above changes in designation were earlier recommended by the Nomination and Remuneration Committee at its meeting held on August 12, 2026 and subsequently approved by the Board of Directors at its meeting held on same day subject to the approval of the Members of the Company at the 39th Annual General Meeting. The requisite approval of the Members has now been obtained. The disclosures required under Regulation 30 of the SEBI LODR Regulations read with the applicable SEBI Circular are enclosed herewith as Annexure A. Reconstitution of Statutory Committees Consequent upon the approval of the Members for the change in designation of Mr. Ravindra Kumar Kothari from Non-Executive Director to Whole-Time Director (Executive Director) and Mr. Virupakshaya Himesh from Whole-Time Director to Non-Executive Director, the Nomination and Remuneration Committee (“NRC”) and the Stakeholders’ Relationship Committee (“SRC”) of the Company have been reconstituted with effect from October 1, 2026, in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The proposed reconstitution of the NRC and SRC was recommended by the NRC at its meeting held on August 12, 2026 and approved by the Board of Directors at its meeting held on the same day, subject to the approval of the Members for the aforesaid change in designation of the Directors. Pursuant to the approval accorded by the Members at the 39th Annual General Meeting held on September 24, 2026, the NRC and SRC have been reconstituted with effect from October 1, 2026, as follows: 1. Mr. Virupakshaya Himesh has been inducted as a Member of the NRC and SRC. 2. Mr. Ravindra Kumar Kothari has ceased to be a Member of the NRC and SRC. Accordingly, the revised composition of the NRC and SRC shall be effective from October 1, 2026. Please takes this intimation on your records Thanking You. For Bal Pharma Limited Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681 Annexure: A The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 are given as under. Change of Designations of Directors: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Particulars Mr. Ravindra Kumar Kothari Mr. Virupakshaya Himesh Reason for change Change in designation from Change in designation from Non-Executive Director to Executive Director to Non- Executive Director Executive Director Date of appointment/re- Change of Designation will Change of Designation will designation effective from 01st October effective from 01st October 2026 2026 Term of appointment Not applicable (Director Not applicable (Director already on the Board) already on the Board) Brief profile Not applicable (Director Not applicable (Director already on the Board) already on the Board) disclosure of relationships Not applicable Not applicable between directors (in case of appointment of a director). Information as required under The Director being appointed The Director being appointed Circular No. is not debarred from holding is not debarred from holding LIST/COMP/14/2018- 19 and the office of director by virtue the office of director by virtue NSE/CML/ 2018/02 dated of any SEBI order or any other of any SEBI order or any other June 20, 2018, issued by the such authority. such authority. BSE and NSE, respectively Shareholdings 500 28,420